displaying all

Category	Title
GPS	GPS-0. Nationwide surveys among the general population: Bibliographic references
GPS	GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population Part (i) Lifetime prevalence all adults
GPS	GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population Part (ii) Survey methods
GPS	GPS-2. Lifetime prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
GPS	GPS-3. Last year prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population
GPS	GPS-4. Last year prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
GPS	GPS-5. Last month prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population
GPS	GPS-6. Last month prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
GPS	GPS-7. Frequency of use of cannabis among all adults (aged 15 to 64 years) and young adults (aged 15 to 34 years) in nationwide surveys among the general population Part (i) Frequency of use among all users in last month (percentage) — 2007 field trial
GPS	GPS-7. Frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population Part (ii) Frequency of use among all users in last month (percentage) — 2004 field trial
GPS	GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population. Part (i) Lifetime prevalence all adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population. Part (ii) Survey methods: last survey available for each Member State (from 2000 onwards)
GPS	GPS-9. Lifetime prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-10. Last year prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-11. Last year prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-12. Last month percentage prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-13. Last month prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-14. Lifetime prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
GPS	GPS-15. Last year prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
GPS	GPS-16. Last month prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
GPS	GPS-17. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State (from 2000 onwards)
GPS	GPS-18. Last year prevalence of drug use among the 15–24 age group in nationwide surveys among the general population. Last survey available for each Member State (from 2000 onwards)
GPS	GPS-19. Last month prevalence of drug use among the 15–24 age group in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
GPS	GPS-121. Methodological information for nation-wide surveys among the general population
GPS	GPS-1. Last year prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15- to 24-year-old age group, measured by national population surveys
GPS	GPS-2. Continuation rates of cannabis (last year and last month use among lifetime users) in the general population, as measured by national surveys Part (i) Lifetime prevalence all adults
GPS	GPS-3. Last month prevalence of cannabis among the 15-to 24-year old age group, measured by national surveys
GPS	GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys Part (i) All countries
GPS	GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys Part (ii) Countries with three or more surveys
GPS	GPS-5. Last year prevalence of amphetamines among young adults aged 15 to 34 and 15 to 24, measured by population surveys
GPS	GPS-6. Last year prevalence of amphetamines among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS	GPS-7. Last month prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
GPS	GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (i) All Member States with available information
GPS	GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (ii) Males 15 to 24 in Member States with higher prevalence rates
GPS	GPS-10. Last year prevalence of cannabis by age group in United Kingdom (E&W), measured by national population surveys
GPS	GPS-11. Continuation rates of ecstasy (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys — last survey available Part (i) Last year prevalence in some of the EU-15 Member States
GPS	GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys — last survey available Part (ii) Last year prevalence in some ‘new’ EU Member States
GPS	GPS-13. Last year prevalence of cocaine among all young adults (aged 15 to 34 ) by gender, measured by national surveys
GPS	GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-15. Last year prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS	GPS-16. Continuation rates of cocaine (last year and last month use among lifetime users) in the general population, measured by national surveys
GPS	GPS-17. Last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34)
GPS	GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (i) Cannabis use — lifetime experience, last year and last month prevalence
GPS	GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (ii) Cocaine, amphetamines and ecstasy use — lifetime experience, last year and last month prevalence
GPS	GPS-20. Figure GPS-20. Lifetime and last year prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA — last survey available for each country
GPS	GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-22. Continuation rates of amphetamines (last year and last month use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (i) United Kingdom (E&W)
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (ii) Denmark
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (iii) Germany
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (iv) Spain
GPS	GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (v) France
EYE	EYE-0. School surveys: Sources
EYE	EYE-1. Recent school surveys (2003–06): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old
EYE	EYE-2. Recent school surveys (2003–06): percentage lifetime prevalence (LTP) of psychoactive substance use and percentage last month prevalence (LMP) of cannabis among students aged 17 to 18 years
EYE	EYE-3. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years
EYE	EYE-4. ESPAD 2003 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Part (i) All students
EYE	EYE-4. ESPAD 2003 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Part (ii) Males
EYE	EYE-4. ESPAD 2003 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Part (iii) Females
EYE	EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years Part (i) All students
EYE	EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years Part (ii) Males
EYE	EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years Part (iii) Females
EYE	EYE-6. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (i) All students
EYE	EYE-6. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (ii) Males
EYE	EYE-6. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (iii) Females
EYE	EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years Part (i) All students
EYE	EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years Part (ii) Males
EYE	EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years Part (iii) Females
EYE	EYE-8. HBSC school surveys (2005/06): percentage lifetime prevalence of cannabis use among students aged 15–16 years old
EYE	EYE-9. HBSC school surveys (2005/06): percentage of types of cannabis use during the last 12 months among students aged 15–16 years old Part (i) All students
EYE	EYE-9. HBSC school surveys (2005/06): percentage of types of cannabis use during the last 12 months among students aged 15–16 years old Part (ii) Males
EYE	EYE-9. HBSC school surveys (2005/06): percentage of types of cannabis use during the last 12 months among students aged 15–16 years old Part (iii) Females
EYE	EYE-1. Comparison of polydrug use prevalence in the past month between all school students (aged 15–16) with those who use cannabis in 2003
EYE	EYE-2. Comparison of polydrug use prevalence in the last month between all school students (aged 15–16) with those who used ecstasy in 2003
EYE	EYE-4. Changes between 2001/02 and 2005/06 in prevalence of heavy cannabis use among school students aged 15–16
PDU	PDU-0. Prevalence of problem drug use at national and subnational level: bibliographic references
PDU	PDU-1. Prevalence of problem drug use at national level: Summary Table, 2002–06, rate per 1000 aged 15–64 Part (i) Overall problem drug use
PDU	PDU-1. Prevalence of problem drug use at national level: Summary Table, 2002–06, rate per 1000 aged 15–65 Part (ii) Injecting drug use
PDU	PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2001 to 2006 (rate per 1 000 population aged 15 to 64): Combined estimates per country Part (i) Estimated trends of overall problem drug use
PDU	PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2001 to 2006 (rate per 1 000 population aged 15 to 64): Combined estimates per country Part (ii) Estimated trends of problem opioid use
PDU	PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2001 to 2006 (rate per 1 000 population aged 15 to 64): Combined estimates per country Part (iii) Estimated trends of injecting drug use
PDU	PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2001 to 2006 (rate per 1 000 population aged 15 to 64): Combined estimates per country Part (iv) Estimated trends of problem stimulant use
PDU	PDU-102. Prevalence of problem drug use at national level - full listing of studies Part (i) Problem drug use
PDU	PDU-102. Prevalence of problem drug use at national level - full listing of studies Part (ii) Injecting drug use
PDU	PDU-103. Prevalence of problem drug use at subnational level - full list of studies Part (i) Problem drug users
PDU	PDU-103. Prevalence of problem drug use at subnational level - full list of studies Part (ii) Injecting drug users
PDU	PDU-105. Studies of IDU providing information on sample structure by age and years injecting Part (i) IDUs distribution by age
PDU	PDU-105. Studies of IDU providing information on sample structure by age and years injecting Part (ii) IDUs distribution by years injecting
PDU	PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2002 to 2006 — last study available Part (i) Estimates of overall problem drug use
PDU	PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2002 to 2006 – last study available Part (ii) Estimates for problem opioid use
PDU	PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2002 to 2006 — last study available
PDU	PDU-3. Percentage of new and of young injectors reported in samples of injecting drug users tested for HIV or HCV, studies from 2004 to 2006
DUP	DUP-0. Prevalence of drug use among prisoners — Sources and bibliographic references
DUP	DUP-1. Prevalence of lifetime drug use among prisoners, 2000–06
DUP	DUP-2. Prevalence of lifetime injecting drug use among prisoners, 2000–06
DUP	DUP-3. Prevalence of drug use within prison among prisoners, 2000–07
DUP	DUP-4. Prevalence of injecting drug use within prison among prisoners, 2000–07
DUP	DUP-105. Prevalence (percentage) of drug use among prisoners in EU Member States and Norway – full listing of studies
INF	INF-0. Bibliographic references
INF	INF-1. Prevalence of HIV infection among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
INF	INF-2. Prevalence of HCV antibody among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
INF	INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
INF	INF-18. Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 2001 to 2006, samples with average prevalence above 5 %
INF	INF-19. Trends in HCV antibody prevalence in national and subnational samples of injecting drug users 2001 to 2006, countries with average prevalence above 50 %.
INF	INF-104. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2006, (a) cases per million population, (b) number of cases and (c) population sizes
INF	INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all cases with known risk factor
INF	INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all notified cases with known risk factor
INF	INF-107. Incidence studies of hepatitis C virus infection among injecting drug users in the EU
INF	INF-108. Prevalence of HIV infection (percentage) among injecting drug users, 1991 to 2007
INF	INF-109. Prevalence of HIV infection (percentage) among injecting drug users under age 25, 1991 to 2007
INF	INF-110. Prevalence of HIV infection (percentage) among new injecting drug users (injecting less than 2 years), 1991 to 2006
INF	INF-111. Prevalence of hepatitis C infection (percentage) among injecting drug users, 1991 to 2007
INF	INF-112. Prevalence of hepatitis C infection (percentage) among injecting drug users under age 25, 1991 to 2007
INF	INF-113. Prevalence of hepatitis C infection (percentage) among new injecting drug users (injecting less than 2 years), 1991 to 2006
INF	INF-114. Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users, 1991 to 2006
INF	INF-115. Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users, 1991 to 2006
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006 Part (i) Prevalence of HIV infection (percentage) among injecting drug users in prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006 Part (ii) Prevalence of hepatitis C infection (percentage) among injecting drug users in prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006 Part (iii) Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users in prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006 Part (iv) Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users in prison
DRD	DRD-0. Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references
DRD	DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (i) Demographic characteristics, 2006 or last year with available information
DRD	DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (ii) Numbers of drug-induced deaths and toxicology, 2006 or last year with available information
DRD	DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (iii) Demographic characteristics and toxicology, 1990 or closest year with available information
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (i) Total drug-induced deaths, 1995 to 2006
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (ii) Male drug-induced deaths, 1995 to 2006
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (iii) Female drug-induced deaths, 1995 to 2006
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (iv) Total drug-induced deaths under the age of 25 years, 1995 to 2006
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (v) Totals and indexes, 1995 to 2006
DRD	DRD-3. Number of drug-induced deaths recorded in EU Member States and Norway according to EMCDDA standard definition 'Selection B', 1995 to 2006
DRD	DRD-4. Number of drug-induced deaths recorded in EU Member States according to EMCDDA standard definition 'Selection D', 1995 to 2006
DRD	DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (i) Population mortality rates, 2006 or last year with available information
DRD	DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (ii) Proportional mortality due to drug-induced deaths, 2006 or last year with available information
DRD	DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (iii) Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use
DRD	DRD-106. Methodological features of drug-induced deaths reported by Reitox national focal points (Based on national definitions – Reitox Standard Table 5).
DRD	DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (i) Total drug-induced deaths, 1985 to 2006
DRD	DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (ii) Totals and indexes, 1985 to 2006
DRD	DRD-108. Drug-induced deaths: Detailed qualitative national information on deaths due to specific substances in EU Member States (2007 National reports)
DRD	DRD-1. Proportion of drug-induced deaths that show presence of opioids for the most recent year reported
DRD	DRD-2. Proportion of drug-induced deaths occurring under the age of 25 years in 2004
DRD	DRD-3. Trends in mean age of drug-induced deaths in some of the EU-15 Member States, 1990 to 2006
DRD	DRD-4. Trends in mean age of drug-induced deaths in some new EU Member States, 1990 to 2006
DRD	DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 Part (i) Indexed trend in the EU-15 Member States and Norway 1990–2005
DRD	DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 Part (ii) Indexed trend in the new Member States, 1990–2005
DRD	DRD-6. Indexed overall trends for males and females in drug-induced deaths in the EU-15 Member States and Norway, 1990 to 2005
DRD	DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries Part (i) Mortality rates among all adults (15 to 64 years) due to drug-related deaths and 95 % confidence intervals for last year available
DRD	DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries Part (ii) Mortality rates among all adults (15 to 64 years) due to drug-related deaths and estimated mortality rates due to Aids attributable to injection drug use
DRD	DRD-8. Indexed long term trend in drug-induced deaths in the EU 15 Member States and Norway, 1985 to 2005
DRD	DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2006 (three-year moving average) Part (i) Some EU Member States and Norway, 1990 to 2006
DRD	DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2006 (three-year moving average) Part (ii) Some EU Member States, 1990 to 2006
DRD	DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2006 (three-year moving average) Part (iii) Some EU countries, 1990 to 2006
DRD	DRD-10. Mean age of drug-induced deaths in EU Member States, last year with available data
DRD	DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (i) Index in some Member States, 1985 to 2006
DRD	DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (ii) Index in some Member States, 1985 to 2006
DRD	DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (iii) Index in some Member States, 1985 to 2006
DRD	DRD-12. Proportional change in drug-induced deaths in the EU Member States Part (i) Changes between 2000 and 2003
DRD	DRD-12. Proportional change in drug-induced deaths in the EU Member States Part (ii) Changes between 2003 and 2004/5
DRD	DRD-12. Proportional change in drug-induced deaths in the EU Member States Part (iii) Changes between 2001 and 2005/6
DRD	DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions Part (i) EU-15 Member States and Norway 1990–2005
DRD	DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions Part (ii) New Member States, 1990–2005
DLO	DLO-1. Drug law offences 1995 to 2006 Part (i) Number of reports
DLO	DLO-1. Drug law offences 1995 to 2006 Part (ii) Methodological notes
DLO	DLO-2. Offence types in reports for drug law offences Part (i) Percentage of all reports for drug law offences
DLO	DLO-2. Offence types in reports for drug law offences Part (ii) Methodological notes
DLO	DLO-3. Drug types in reports for drug law offences Part (i) Percentage of all reports for drug law offences
DLO	DLO-3. Drug types in reports for drug law offences Part (ii) Methodological notes
DLO	DLO-4. Drug law offences related to drug use or possession for use, 2000 to 2006 Part (i) Number and percentage
DLO	DLO-4. Drug law offences related to drug use or possession for use, 2000 to 2006 Part (ii) Methodological notes
DLO	DLO-5. Drug law offences related to drug trafficking, 2000 to 2006 Part (i) Number and percentage
DLO	DLO-5. Drug law offences related to drug trafficking, 2000 to 2006 Part (ii) Methodological notes
DLO	DLO-6. Cannabis-related offences, 2000 to 2006 Part (i) Number and percentage of all drug law offences
DLO	DLO-6. Cannabis-related offences, 2000 to 2006 Part (ii) Methodological notes
DLO	DLO-7. Heroin-related offences, 2000 to 2006 Part (i) Number and percentage of all drug law offences
DLO	DLO-7. Heroin-related offences, 2000 to 2006 Part (ii) Methodological notes
DLO	DLO-8. Cocaine-related offences, 2000 to 2006 Part (i) Number and percentage of all drug law offences
DLO	DLO-8. Cocaine-related offences, 2000 to 2006 Part (ii) Methodological notes
DLO	DLO-109. Number of reports for drug law offences 1985 to 2006 Part (i) Number of reports
DLO	DLO-109. Number of reports for drug law offences 1985 to 2006 Part (ii) Methodological notes
DLO	DLO-1. Drug law offences in Europe, 2001–06 Part (i) EU-15 Member States and Norway
DLO	DLO-1. Drug law offences in Europe, 2001–06 Part (ii) Other EU Member States, Croatia and Turkey
DLO	DLO-2. Indexed trends in reports for drug-related offences by broad type of offence in the EU Member States 2001–06
DLO	DLO-3. Indexed trends in reports for drug law offences by type of drug in the EU Member States 2001–06
DLO	DLO-4. Indexed trends in reports for offences related to drug use or possession for use in the EU Member States 2001–06
DLO	DLO-5. Cannabis-related offences in Europe, 2001–06 Part (i) EU-15 Member States and Norway
DLO	DLO-5. Cannabis-related offences in Europe, 2001–06 Part (ii) Other EU Member States, Croatia and Turkey
DLO	DLO-6. Cocaine-related offences in Europe, 2001–06 Part (i) EU-15 Member States and Norway
DLO	DLO-6. Cocaine-related offences in Europe, 2001–06 Part (ii) Other EU Member States, Croatia and Turkey
DLO	DLO-7. Heroin-related offences in Europe, 2001–06 Part (i) EU-15 Member States and Norway
DLO	DLO-7. Heroin-related offences in Europe, 2001–06 Part (ii) Other EU Member States, Croatia and Turkey
TDI	TDI-1. Data sources for data on clients entering treatment in 2006
TDI	TDI-2. Trends in the number of clients entering treatment and the number of reporting treatment centres, 1996 to 2006 Part (i) Total numbers of new clients entering treatment
TDI	TDI-2. Trends in the number of clients entering treatment and the number of reporting treatment centres, 1996 to 2006 Part (ii) Total numbers of all clients entering treatment
TDI	TDI-2. Trends in the number of clients entering treatment and the number of reporting treatment centres, 1996 to 2006 Part (iii) Numbers of treatment units covered for reporting clients entering treatment
TDI	TDI-2. Trends in the number of clients entering treatment and the number of reporting treatment centres, 1996 to 2006 Part (iv) Types of units covered for reporting clients entering treatment
TDI	TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006 Part (i) Percentage of new clients using heroin
TDI	TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006 Part (ii) Percentage of new clients using cocaine
TDI	TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006 Part (iii) Percentage of new clients using stimulants (amphetamines and MDMA)
TDI	TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006 Part (iv) Percentage of new clients using cannabis
TDI	TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available Part (i) Demographics of new clients entering treatment
TDI	TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available Part (ii) Primary drug type used (percent of new clients using) and of those, the percent injecting it
TDI	TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available Part (i) Demographics of all clients entering treatment
TDI	TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available Part (ii) Primary drug type used by clients (percentage of all clients) and of those, the percentage injecting the drug
TDI	TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available Part (iii) Demographics of all men entering treatment
TDI	TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available Part (iv) Demographics of all women entering treatment
TDI	TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available Part (v) Primary drug type used by male clients (percentage of all male clients)
TDI	TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available Part (vi) Primary drug type used by female clients (percentage of all female clients)
TDI	TDI-6. Incidence of treatment demands for drug use: new clients entering treatment in 2006 (rate per 100 000 population)
TDI	TDI-7. Data coverage in 2006 for countries supplying data Part (i) Number of new and all clients entering treatment by type of treatment centre
TDI	TDI-7. Data coverage in 2006 for countries supplying data Part (ii) Number and type of treatment centre
TDI	TDI-8. Amphetamines, ecstasy and other non-cocaine stimulants: primary use among new and all clients entering treatment in 2006 for countries supplying data Part (i) All clients with primary use of stimulants other than cocaine in treatment centres reported for the country
TDI	TDI-8. Amphetamines, ecstasy and other non-cocaine stimulants: primary use among new and all clients entering treatment in 2006 for countries supplying data Part (ii) New clients with primary use of stimulants other than cocaine in treatment centres reported for the country
TDI	TDI-9. Mean age and gender distribution among new and all clients entering outpatient treatment in 2006
TDI	TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006 Part (i) Percentage distribution of new outpatient clients by age group for each primary drug
TDI	TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006 Part (ii) Percentage distribution of new outpatient clients by primary drug for each age group
TDI	TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006 Part (iii) Percentage distribution of all outpatient clients by age group for each primary drug
TDI	TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006 Part (iv) Percentage distribution of all outpatient clients by primary drug for each age group
TDI	TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006 Part (v) Percentage distribution of new inpatient clients by age group for each primary drug
TDI	TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006 Part (vi) Percentage distribution of new inpatient clients by primary drug for each age group
TDI	TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006 Part (vii) Percentage distribution of all inpatient clients by age group for each primary drug
TDI	TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006 Part (viii) Percentage distribution of all inpatient clients by primary drug for each age group
TDI	TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006 Part (i) Percentage distribution of new outpatient clients by age at first use for each primary drug
TDI	TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006 Part (ii) Percentage distribution of new outpatient clients by primary drug for age at first use
TDI	TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006 Part (iii) Percentage distribution of all outpatient clients by age at first use for each primary drug
TDI	TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006 Part (iv) Percentage distribution of all outpatient clients by primary drug for age at first use
TDI	TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006 Part (v) Percentage distribution of new inpatient clients by age at first use for each primary drug
TDI	TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006 Part (vi) Percentage distribution of new inpatient clients by primary drug for age at first use
TDI	TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006 Part (vii) Percentage distribution of all inpatient clients by age at first use for each primary drug
TDI	TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006 Part (viii) Percentage distribution of all inpatient clients by primary drug for age at first use
TDI	TDI-12. Percentage distribution of educational level for clients entering treatment in 2006 Part (i) New clients entering outpatient treatment
TDI	TDI-12. Percentage distribution of educational level for clients entering treatment in 2006 Part (ii) All clients entering outpatient treatment
TDI	TDI-12. Percentage distribution of educational level for clients entering treatment in 2006 Part (iii) New clients entering inpatient treatment
TDI	TDI-12. Percentage distribution of educational level for clients entering treatment in 2006 Part (iv) All clients entering inpatient treatment
TDI	TDI-13. Percentage distribution of labour status for clients entering treatment in 2006 Part (i) New clients entering outpatient treatment
TDI	TDI-13. Percentage distribution of labour status for clients entering treatment in 2006 Part (ii) All clients entering outpatient treatment
TDI	TDI-13. Percentage distribution of labour status for clients entering treatment in 2006 Part (iii) New clients entering inpatient treatment
TDI	TDI-13. Percentage distribution of labour status for clients entering treatment in 2006 Part (iv) All clients entering inpatient treatment
TDI	TDI-14. Percentage distribution of accommodation arrangements (persons with whom the client is living) of clients entering treatment in 2006 Part (i) New clients entering outpatient treatment
TDI	TDI-14. Percentage distribution of accommodation arrangements (persons with whom the client is living) of clients entering treatment in 2006 Part (ii) All clients entering outpatient treatment
TDI	TDI-14. Percentage distribution of accommodation arrangements (persons with whom the client is living) of clients entering treatment in 2006 Part (iii) New clients entering inpatient treatment
TDI	TDI-14. Percentage distribution of accommodation arrangements (persons with whom the client is living) of clients entering treatment in 2006 Part (iv) All clients entering inpatient treatment
TDI	TDI-15. Percentage distribution of living conditions for clients entering treatment in 2006 Part (i) New clients entering outpatient treatment
TDI	TDI-15. Percentage distribution of living conditions for clients entering treatment in 2006 Part (ii) All clients entering outpatient treatment
TDI	TDI-15. Percentage distribution of living conditions for clients entering treatment in 2006 Part (iii) New clients entering inpatient treatment
TDI	TDI-15. Percentage distribution of living conditions for clients entering treatment in 2006 Part (iv) All clients entering inpatient treatment
TDI	TDI-16. Percentage distribution of source of referral for new clients entering outpatient and inpatient treatment in 2006 Part (i) New clients entering outpatient treatment
TDI	TDI-16. Percentage distribution of source of referral for new clients entering outpatient and inpatient treatment in 2006 Part (ii) New clients entering inpatient treatment
TDI	TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006 Part (i) Percentage distribution of route of administration amongst new clients with opioids as primary drug
TDI	TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006 Part (ii) Percentage distribution of route of administration amongst new clients with cocaine (HCl and crack) as primary drug
TDI	TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006 Part (iii) Percentage distribution of route of administration amongst new clients with stimulants (other than cocaine) as primary drug
TDI	TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006 Part (iv) Percentage distribution of route of administration amongst new clients with hypnotics and sedatives as primary drug
TDI	TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006 Part (v) Percentage distribution of route of administration amongst all clients with opioids as primary drug
TDI	TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006 Part (vi) Percentage distribution of route of administration amongst all clients with cocaine (HCl and crack) as primary drug
TDI	TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006 Part (vii) Percentage distribution of route of administration amongst all clients with stimulants (other than cocaine) as primary drug
TDI	TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006 Part (viii) Percentage distribution of route of administration amongst all clients with hypnotics and sedatives as primary drug
TDI	TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2006 Part (i) Percentage distribution amongst new outpatient clients
TDI	TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2006 Part (ii) Percentage distribution amongst all outpatient clients
TDI	TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2006 Part (iii) Percentage distribution amongst new inpatient clients
TDI	TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2006 Part (iv) Percentage distribution amongst all inpatient clients
TDI	TDI-19. Percentage distribution of primary drug among new and all clients entering outpatient and inpatient treatment in 2006 Part (i) New clients entering outpatient treatment
TDI	TDI-19. Percentage distribution of primary drug among new and all clients entering outpatient and inpatient treatment in 2006 Part (ii) All clients entering outpatient treatment
TDI	TDI-19. Percentage distribution of primary drug among new and all clients entering outpatient and inpatient treatment in 2006 Part (iii) New clients entering inpatient treatment
TDI	TDI-19. Percentage distribution of primary drug among new and all clients entering outpatient and inpatient treatment in 2006 Part (iv) All clients entering inpatient treatment
TDI	TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2006 and in the general population Part (i) New clients entering outpatient treatment
TDI	TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2006 and in the general population Part (ii) All clients entering outpatient treatment
TDI	TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2006 and in the general population Part (iii) New clients entering inpatient treatment
TDI	TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2006 and in the general population Part (iv) All clients entering inpatient treatment
TDI	TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006 Part (i) Ratio of males to females among new clients entering outpatient treatment
TDI	TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006 Part (ii) Ratio of males to females among all clients entering outpatient treatment
TDI	TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006 Part (iii) Ratio of males to females among new clients entering inpatient treatment
TDI	TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006 Part (iv) Ratio of males to females among all clients entering inpatient treatment
TDI	TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2006: average for those EU countries supplying data Part (i) Outpatient centres
TDI	TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2006: average for those EU countries supplying data Part (ii) Inpatient centres
TDI	TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type Part (i) Percentage distribution of secondary drug by primary drug for the EU overall
TDI	TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type Part (ii) All clients with opioids as primary drug type: number of episodes reporting the stated drug as secondary
TDI	TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type Part (iii) All clients with cocaine as primary drug type: number of episodes reporting the stated drug as secondary
TDI	TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type Part (iv) All clients with cannabis as primary drug: number of episodes reporting the stated drug as secondary
TDI	TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type Part (v) All clients with stimulants other than cocaine as primary drug type: number of episodes reporting the stated drug as secondary
TDI	TDI-24. Percentage of clients by type of treatment centres and by primary drug for all and new clients entering treatment in 2006 (outpatient, inpatient and other types of treatment centres) Part (i) All clients
TDI	TDI-24. Percentage of outpatient and inpatient clients by primary drug for all and new clients entering treatment in 2006 Part (ii) New clients
TDI	TDI-25. Percentage distribution of age by gender among all clients entering outpatient treatment with primary drug: opioids, cocaine, stimulants and cannabis in 2006 for countries supplying data
TDI	TDI-32. Mean age by gender by primary drug among all clients entering outpatient and inpatient treatment in 2006 Part (i) Outpatient clients
TDI	TDI-32. Mean age by gender by primary drug among all clients entering outpatient and inpatient treatment in 2006 Part (ii) Inpatient clients
TDI	TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering outpatient and inpatient treatment in 2006 Part (i) Outpatient treatment centres
TDI	TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering outpatient and inpatient treatment in 2006 Part (ii) Inpatient treatment centres
TDI	TDI-34. Outpatient and inpatient treatment centres and treatment units in prison: number of all clients entering treatment and number and percentages of units covered in four countries supplying data in 2006
TDI	TDI-35. Outpatient and inpatient treatment centres and treatment units in prison: percentage distribution of all clients by primary drug in four countries supplying data in 2006
TDI	TDI-36. Trends in primary amphetamines use among new clients entering treatment between 2001 and 2006 in four countries
TDI	TDI-37. Amphetamines and ecstasy clients entering drug treatment in 2006 Part (i) Outpatient and inpatient clients entering treatment for primary amphetamines and ecstasy use in 2006
TDI	TDI-37. Amphetamines and ecstasy clients entering drug treatment in 2006 Part (ii) Mean age and gender ratio among primary amphetamines or ecstasy clients entering treatment in 2006
TDI	TDI-37. Amphetamines and ecstasy clients entering drug treatment in 2006 Part (iii) Secondary drugs among outpatient and inpatient clients entering treatment for primary amphetamines and ecstasy use (number of citations)
TDI	TDI-38. All clients in treatment (treatment prevalence) for primary use of amphetamines, ecstasy and other stimulants (other than cocaine) in countries reporting in 2006: demographics and patterns of drug use
TDI	TDI-39. Treatment prevalence in 2006 in nine countries: percentage distribution of all treatment clients by primary drug at treatment entry (first treatment incidence, total treatment incidence, total treatment prevalence)
TDI	TDI-40. Treatment Prevalence in 2006: proportion of injectors by primary drug (excluding cannabis) among treated clients in 2006 in nine countries (first treatment incidence, total treatment incidence, total treatment prevalence)
TDI	TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(i) Number of clients using opioids as primary drug
TDI	TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(ii) Number of clients using cocaine (HCl and 'crack') as primary drug
TDI	TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI	TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(iv) Number of clients using hallucinogens as primary drug
TDI	TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (v) Number of clients using hypnotics and sedatives as primary drug
TDI	TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI	TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI	TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI	TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(i) Number of clients using opioids as primary drug
TDI	TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(ii) Number of clients using cocaine (HCl and 'crack') as primary drug
TDI	TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI	TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(iv) Number of clients using hallucinogens as primary drug
TDI	TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (v) Number of clients using hypnotics and sedatives as primary drug
TDI	TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI	TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI	TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI	TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(i) Number of clients using opioids as primary drug
TDI	TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(ii) Number of clients using cocaine (HCl and 'crack') as primary drug
TDI	TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI	TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(iv) Number of clients using hallucinogens as primary drug
TDI	TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (v) Number of clients using hypnotics and sedatives as primary drug
TDI	TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI	TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI	TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI	TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(i) Number of clients using opioids as primary drug
TDI	TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(ii) Number of clients using cocaine (HCl and 'crack') as primary drug
TDI	TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI	TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part(iv) Number of clients using hallucinogens as primary drug
TDI	TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (v) Number of clients using hypnotics and sedatives as primary drug
TDI	TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI	TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI	TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI	TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (i) Number of clients using opiates as primary drug
TDI	TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (ii) Number of clients using cocaine as primary drug
TDI	TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI	TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (iv) Number of clients using hypnotics and sedatives as primary drug
TDI	TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (v) Number of clients using hallucinogens as primary drug
TDI	TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI	TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI	TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI	TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (i) Number of clients using opiates as primary drug
TDI	TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (ii) Number of clients using cocaine as primary drug
TDI	TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI	TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (iv) Number of clients using hypnotics and sedatives as primary drug
TDI	TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (v) Number of clients using hallucinogens as primary drug
TDI	TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI	TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI	TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI	TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (i) Number of clients using opioids as primary drug
TDI	TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (ii) Number of clients using cocaine as primary drug
TDI	TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI	TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (iv) Number of clients using hypnotics and sedatives as primary drug
TDI	TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (v) Number of clients using hallucinogens as primary drug
TDI	TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (vi) Number of clients using volatile/inhalants as primary drug
TDI	TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI	TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI	TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (i) Number of clients using opiates as primary drug
TDI	TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (ii) Number of clients using cocaine as primary drug
TDI	TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
TDI	TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (iv) Number of clients using hypnotics and sedatives as primary drug
TDI	TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (v) Number of clients using hallucinogens as primary drug
TDI	TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (vi) Number of clients using volatile inhalants as primary drug
TDI	TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (vii) Number of clients using cannabis as primary drug
TDI	TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data Part (viii) Number of clients using other drugs as primary drugs
TDI	TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006 Part (i) Percentage distribution amongst new clients with opioids as primary drug
TDI	TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006 Part (ii) Percentage distribution amongst all clients with opioids as primary drug
TDI	TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006 Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
TDI	TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006 Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
TDI	TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006 Part (v) Percentage distribution amongst new clients with amphetamines and MDMA as primary drug
TDI	TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006 Part (vi) Percentage distribution amongst all clients with amphetamines and MDMA as primary drug
TDI	TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006 Part (vii) Percentage distribution amongst new clients with cocaine as primary drug
TDI	TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006 Part (viii) Percentage distribution amongst all clients with cocaine as primary drug
TDI	TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006 Part (i) Percentage distribution amongst new clients with opioids as primary drug
TDI	TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006 Part (ii) Percentage distribution amongst all clients with opioids as primary drug
TDI	TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006 Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
TDI	TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006 Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
TDI	TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006 Part (v) Percentage distribution amongst new clients with amphetamines and MDMA as primary drug
TDI	TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006 Part (vi) Percentage distribution amongst all clients with amphetamines and MDMA as primary drug
TDI	TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006 Part (vii) Percentage distribution amongst new clients with cocaine as primary drug
TDI	TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006 Part (viii) Percentage distribution amongst all clients with cocaine as primary drug
TDI	TDI-113. All clients entering treatment for opioids by type of opioid misused for countries supplying data in 2006
TDI	TDI-114. Primary opioids distribution (percent) among all clients entering treatment by type of treatment centre in three countries supplying data in 2006
TDI	TDI-115. Primary cocaine use – HCL and Crack – among new and all clients entering outpatient drug treatment in 2006 for countries supplying data Part (i) All clients
TDI	TDI-115. Primary cocaine use – HCL and Crack – among new and all clients entering outpatient drug treatment in 2006 for countries supplying data Part (ii) New clients
TDI	TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2002 to 2006 Part (i) Percentage distribution by primary drug
TDI	TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2002 to 2006 Part (ii) Numbers of clients by primary drug
TDI	TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2006 in 24 EU Member States Part (i) New clients
TDI	TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2006 in 24 EU Member States Part (ii) All clients
TDI	TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2002 to 2006 Part (i) Percentage distribution by primary drug
TDI	TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2002 to 2006 Part (ii) Numbers of clients by primary drug
TDI	TDI-6. New and all outpatient clients by age group in 2006 for those countries supplying data
TDI	TDI-11. Clients entering first treatment, all clients entering treatment, total clients in treatment, summary of nine EU countries reporting in 2006 Part (i) Number of clients in treatment
TDI	TDI-11. Clients entering first treatment, all clients entering treatment, total clients in treatment, summary of nine EU countries reporting in 2006 Part (ii) Percentage of clients in treatment with opioids, cannabis or other drugs as primary drugs
HSR	HSR-1. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT) and heroin-assisted treatment, including trials
HSR	HSR-2. Legal framework and practice of substitution treatment initiation
HSR	HSR-3. Estimated number of clients in methadone treatment and of clients receiving any opioid substitution Part (i): Estimates of clients in methadone treatment or opioid substitution in EU-27, Croatia, Turkey and Norway, 2005 and 2006
HSR	HSR-3. Estimated number of clients in methadone treatment and of clients receiving any opioid substitution Part (ii) Methodological notes for EU-27, Norway and Croatia, 2005 and 2006
HSR	HSR-4. Year of introduction of needle and syringe programmes and types of programmes available in 2006
HSR	HSR-5. Number of syringes provided through needle and syringe programmes 2005–06
HSR	HSR-1. Number of opioid maintenance treatment clients as rate per 100 of the estimated number of problem opioid users, 2005–06
SZR	SZR-1. Number of cannabis resin seizures, 1995 to 2006
SZR	SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2006
SZR	SZR-3. Number of herbal cannabis seizures, 1995 to 2006
SZR	SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2006
SZR	SZR-5. Number of seizures of cannabis plants, 1995 to 2006
SZR	SZR-6. Quantities (number of plants) of cannabis plants seized, 1995 to 2006
SZR	SZR-7. Number of heroin seizures 1995 to 2006
SZR	SZR-8. Quantities (kg) of heroin seized 1995 to 2006
SZR	SZR-9. Number of cocaine seizures 1995 to 2006
SZR	SZR-10. Quantities (kg) of cocaine seized 1995 to 2006
SZR	SZR-11. Number of amphetamine seizures 1995 to 2006
SZR	SZR-12. Quantities (kg) of amphetamine seized 1995 to 2006
SZR	SZR-13. Number of ecstasy seizures 1995 to 2006
SZR	SZR-14. Quantities (tablets) of ecstasy seized 1995 to 2006
SZR	SZR-15. Number of LSD seizures 1995 to 2006
SZR	SZR-16. Quantities (units) of LSD seized 1995 to 2006
SZR	SZR-17. Number of Methamphetamine seizures. 2001 to 2006
SZR	SZR-18. Quantities (kg) of Methamphetamine seized — 2001 to 2006
PPP	PPP-1. Price of cannabis products at retail level, 2006 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP	PPP-1. Price of cannabis products at retail level, 2006 Part (ii) Sources of information
PPP	PPP-2. Price of heroin at retail level, 2006 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP	PPP-2. Price of heroin at retail level, 2006 Part (ii) Sources of information
PPP	PPP-3. Price of cocaine products at retail level, 2006 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP	PPP-3. Price of cocaine products at retail level, 2006 Part (ii) Sources of information
PPP	PPP-4. Price of synthetic drugs at retail level, 2006 Part (i) Minimum, maximum, mean and modal (typical) price in euros
PPP	PPP-4. Price of synthetic drugs at retail level, 2006 Part (ii) Sources of information
PPP	PPP-5. Potency of cannabis products at retail level, 2006 Part (i) Minimum, maximum, mean and modal (typical) potency recorded, measured as percentage of THC content
PPP	PPP-5. Potency of cannabis products at retail level, 2006 Part (ii) Sources of information
PPP	PPP-5. Potency of cannabis products at retail level, 2006 Part (iii) Sampling frame / Type of study
PPP	PPP-6. Purity of heroin at retail level, 2006 Part (i) Minimum, maximum, mean and modal (typical) purity recorded (percentage)
PPP	PPP-6. Purity of heroin at retail level, 2006 Part (ii) Sources of information
PPP	PPP-6. Purity of heroin at retail level, 2006 Part (iii) Sampling frame / Type of study
PPP	PPP-7. Purity of cocaine products at retail level, 2006 Part (i) Minimum, maximum, mean and modal (typical) purity recorded (percentage)
PPP	PPP-7. Purity of cocaine products at retail level, 2006 Part (ii) Sources of information
PPP	PPP-7. Purity of cocaine products at retail level, 2006 Part (iii) Sampling frame / Type of study
PPP	PPP-8. Purity of synthetic drugs at retail level, 2006 Part (i) Minimum, maximum, mean and modal (typical) purity recorded
PPP	PPP-8. Purity of synthetic drugs at retail level, 2006 Part (ii) Sources of information
PPP	PPP-8. Purity of synthetic drugs at retail level, 2006 Part (iii) Sampling frame / Type of study
PPP	PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2001–06
INF	INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million, 1996 to 2006
INF	INF-2. HIV infections newly diagnosed in injecting drug users, by year of report, by country, cases per million, 1996–2006
INF	INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (i) All injecting drug users, 2005 and 2006
INF	INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (ii) Young injecting drug users (under age 25), 2005 to 2006
INF	INF-6. Estimated HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (i) Sample estimates, 2005 to 2006
INF	INF-6. Estimated HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (ii) Estimates for the sub-sample of young injecting drug users (under age 25), 2005 to 2006
INF	INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2005 to 2006, where data are available Part (i) Percentage positive for ever infected (aHBc)
INF	INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2005 to 2006, where data are available Part (ii) Percentage positive for current infection (HBsAg)
EYE	EYE-3. Comparison of frequency of drug use by substance in recreational settings: summary of comparable surveys of 9 European cities in 2006
EYE	EYE-5. Changes between 2001/02 and 2005/06 in prevalence of ever in lifetime cannabis use among school students aged 15–16
PDU	PDU-104. Trends in injecting drug use - percentage currently injecting among all clients entering treatment for primary drug heroin, 2001 to 2006
TDI	TDI-7. New outpatient clients injecting opioid as primary drug from 2003 to 2006 in 13 countries supplying data